JPRN-jRCT2080221942UnknownPhase 1
A PHASE I / II TRIAL OF WEEKLY ABI-007 PLUS GEMCITABINE IN PATIENTS WITH METASTIC PANCREATIC CANCER
Conditions
Trial Snapshot
- Phase
- Phase 1
- Enrollment
- 32
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to <= 79age old (—)
- Sex
- All
Inclusion Criteria
- •Patients must be diagnosed as invasive ductal carcinoma.
- •-Patient must have received no previous therapy.
- •-Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
- •-Written informed consent.
Exclusion Criteria
- •- Patient has pre-existing peripheral neuropathy or symptoms of peripheral sensory.
- •- Patient has uncontrollable pain symptoms.
- •- Patient has uncontrolled or severe diabetes.
- •- Patient has complication or history of serious lung disease, serious heart disease, serious cerebrovascular disorder, or other serious diseases.
Investigators
Similar Trials
Unknown
Phase 1
A Phase I Study of weekly ABI-007 in Combination with TS-1 in Patients with Metastatic Breast CancerMetastatic breast cancerJPRN-jRCT2080221553Taiho Pharmaceutical Co., Ltd.24
Active, not recruiting
Phase 1
Efficacy of ABI-007 plus Gemcitabine or Simplified LV5FU2 as First-line Therapy in Patients with Metastatic Pancreatic Cancer.metastatic pancreatic cancerMedDRA version: 14.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864EUCTR2013-001463-23-FRGERCOR114
Active, not recruiting
Not Applicable
ENSAYO EN FASE I/II DE LA COMBINACIÓN DE GEMCITABINA EN INFUSIÓN PROLONGADA Y PACLITAXEL ADMINISTRADOS DE FORMA QUINCENAL EN EL TRATAMIENTO DE PRIMERA LÍNEA DE PACIENTES CON CÁNCER DE MAMA AVANZADOEUCTR2004-004148-34-ESDr. José Ignacio Chacón López-Muñiz
Active, not recruiting
Not Applicable
A clinical trial to find out whether ABI-007 given together with gemcitabine is as safe and effective as gemcitabine alone, in the treatment of patients with pancreatic cancer that has spread to other organs (metastatic adenocarcinoma of the pancreas)Metastatic adenocarcinoma of the pancreasMedDRA version: 14.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-011305-17-ITABRAXIS BIOSCIENCE LLC AN INDIRECT SUBSIDIARY OF CELGENE CORPORATIO842
Active, not recruiting
Phase 1
A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung CancerPreviously Untreated Extensive Stage Small Cell Lung Cancer (SCLC)MedDRA version: 13.1 Level: LLT Classification code 10041067 Term: Small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-003292-42-GBAmgen Inc213